First De Novo Clearance Signals that Premarket Pathway Is Open for COVID-19 Tests
Just over a year ago, the U.S. Food and Drug Administration (FDA) granted its first Emergency Use Authorization (EUA) for a coronavirus test. On March 17, 2021, the test review process moved to a new phase when the agency cleared a COVID-19 diagnostic via its traditional premarketing pathway for the very first time, thus allowing for marketing of the test beyond the public health emergency. The first test to make the transition from EUA to de novo clearance status is BioFire Diagnostics’ BioFire FilmArray Respiratory Panel (RP) 2.1, which detects 22 different viruses and bacteria associated with SARS-CoV-2 and other respiratory tract infections from a singly nasopharyngeal swab in 45 minutes. The FilmArray RP2.1, which was originally granted EUA clearance on May 1, 2020 (that EUA clearance has now been officially revoked as part of the transition to de novo status) runs on the firm’s FilmArray 2.0 and higher-throughput BioFire Torch systems. BioMérieux subsidiary BioFire has developed a suite of SARS-CoV-2 diagnostic products, including, among others, a singleplex assay for the FilmArray system and the RP 2.1-EZ Panel that detects the coronavirus and 18 other pathogens in point of care and near patient CLIA-waived settings. The FDA noted that it […]
Manufacturer(s) | Product |
---|---|
Abbott Laboratories | EUA for Alinity m Resp-4-Plex assay |
Abbott Laboratories | EUA for AdviseDx SARS-CoV-2 IgG II test |
Inivata | Breakthrough Device Designation for RaDaR liquid biopsy assay |
Zymo Research | 510(k) clearance for use of DNA/RNA Shield Collection Tube for SARS-CoV-2 testing |
GetMyDNA (Gravity Diagnostics affiliate) | EUA for GetMyDNA COVID-19 Test Home Collection Kit |
Gravity Diagnostics + Assurance Scientific Laboratories | EUA for Everlywell COVID-19 Test Home Collection Kit DTC |
Broad Institute | EUA for CRSP SARS-CoV-2 Real-time Reverse Transcriptase-PCR Diagnostic Assay (Version 3) |
Adaptive Technologies | EUA for T-Detect COVID-19 Test blood-based antibodies assay |
Cue Health | EUA for Cue COVID-19 Test for home + over-the-counter use |
Phosphorus Diagnostics LLC | EUA for Phosphorus COVID-19 RT-qPCR Test |
Luminex | EUA for expanded version of multiplex NxTag Respiratory Pathogen Panel (RPP) that includes SARS-CoV-2 target |
Fluidigm | EUA for Advanta Dx SARS-CoV-2 RT-PCR assay for use with Azova COVID-19 Test Collection Kit |
Quidel | EUA for QuickVue At-Home COVID-19 rapid antigen test |
Viracor Eurofins Clinical Diagnostics | EUA for Viracor SARS-CoV-2 assay |
Clinical Enterprise, Inc. | EUA for EmpowerDX COVID-19 Home Collection Kit DTC |
University of Illinois | EUA for CovidShield assay |
Agilent Technologies | Clearance PD-L1 IHC 22C3 pharmDx as companion diagnostic for also newly approved Regeneron Pharmaceuticals and Sanofi’s PD-1 inhibitor cemiplimab-rwlc (Libtayo) as a front-line treatment for advanced non-small cell lung cancer patients with high PD-L1 expression in their tumors |
Inova Diagnostics | 510(k) clearance for Nova Lite DAPI dsDNA Crithidia luciliae Kit |
Subscribe to Clinical Diagnostics Insider to view
Start a Free Trial for immediate access to this article